These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 19968782)
1. Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. Coll M; Martell M; Raurell I; Ezkurdia N; Cuenca S; Hernández-Losa J; Esteban R; Guardia J; Bosch J; Genescà J Liver Int; 2010 Apr; 30(4):593-602. PubMed ID: 19968782 [TBL] [Abstract][Full Text] [Related]
2. Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension. Coll M; Genescà J; Raurell I; Rodríguez-Vilarrupla A; Mejías M; Otero T; Oria M; Esteban R; Guardia J; Bosch J; Martell M J Hepatol; 2008 Jul; 49(1):43-51. PubMed ID: 18457899 [TBL] [Abstract][Full Text] [Related]
3. Blockage of the afferent sensitive pathway prevents sympathetic atrophy and hemodynamic alterations in rat portal hypertension. Ezkurdia N; Coll M; Raurell I; Rodriguez S; Cuenca S; González A; Guardia J; Esteban R; Genescà J; Martell M Liver Int; 2012 Sep; 32(8):1295-305. PubMed ID: 22292477 [TBL] [Abstract][Full Text] [Related]
4. Up-regulation of nNOS and associated increase in nitrergic vasodilation in superior mesenteric arteries in pre-hepatic portal hypertension. Jurzik L; Froh M; Straub RH; Schölmerich J; Wiest R J Hepatol; 2005 Aug; 43(2):258-65. PubMed ID: 15963596 [TBL] [Abstract][Full Text] [Related]
5. Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension. Wiest R; Jurzik L; Moleda L; Froh M; Schnabl B; von Hörsten S; Schölmerich J; Straub RH J Hepatol; 2006 Mar; 44(3):512-9. PubMed ID: 16324766 [TBL] [Abstract][Full Text] [Related]
6. Restriction of drinking water abrogates splanchnic vasodilation and portal hypertension in portal vein-ligated rats. Heinemann A; Schuligoi R; Lippe IT; Stauber RE Pharmacology; 2009; 83(1):26-32. PubMed ID: 18987488 [TBL] [Abstract][Full Text] [Related]
7. Alterations in mechanical properties of mesenteric resistance arteries in experimental portal hypertension. Resch M; Wiest R; Moleda L; Fredersdorf S; Stoelcker B; Schroeder JA; Schölmerich J; Endemann DH Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G849-57. PubMed ID: 19696142 [TBL] [Abstract][Full Text] [Related]
8. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Niederberger M; Ginés P; Martin PY; Tsai P; Morris K; McMurtry I; Schrier RW Hepatology; 1996 Oct; 24(4):947-51. PubMed ID: 8855203 [TBL] [Abstract][Full Text] [Related]
9. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hou MC; Cahill PA; Zhang S; Wang YN; Hendrickson RJ; Redmond EM; Sitzmann JV Hepatology; 1998 Jan; 27(1):20-7. PubMed ID: 9425912 [TBL] [Abstract][Full Text] [Related]
10. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction. Moleda L; Trebicka J; Dietrich P; Gäbele E; Hellerbrand C; Straub RH; Sauerbruch T; Schoelmerich J; Wiest R Gut; 2011 Aug; 60(8):1122-32. PubMed ID: 21317421 [TBL] [Abstract][Full Text] [Related]
11. Does local sympathetic atrophy contribute to splanchnic vasodilation in portal hypertension? Møller S; Stauber RE Liver Int; 2010 Apr; 30(4):499-501. PubMed ID: 20158609 [No Abstract] [Full Text] [Related]
12. Neuropeptide Y restores non-receptor-mediated vasoconstrictive action in superior mesenteric arteries in portal hypertension. Hartl J; Dietrich P; Moleda L; Müller-Schilling M; Wiest R Liver Int; 2015 Dec; 35(12):2556-63. PubMed ID: 26010514 [TBL] [Abstract][Full Text] [Related]
13. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats. Coll M; Rodriguez S; Raurell I; Ezkurdia N; Brull A; Augustin S; Guardia J; Esteban R; Martell M; Genescà J Hepatology; 2012 Nov; 56(5):1849-60. PubMed ID: 22610782 [TBL] [Abstract][Full Text] [Related]
14. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M; Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709 [TBL] [Abstract][Full Text] [Related]
15. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats. Huang HC; Wang SS; Hsin IF; Chang CC; Lee FY; Lin HC; Chuang CL; Lee JY; Hsieh HG; Lee SD Hepatology; 2012 Jul; 56(1):248-58. PubMed ID: 22290687 [TBL] [Abstract][Full Text] [Related]
17. Vasopressin reverses mesenteric hyperemia and vasoconstrictor hyporesponsiveness in anesthetized portal hypertensive rats. Heinemann A; Wachter CH; Fickert P; Trauner M; Stauber RE Hepatology; 1998 Sep; 28(3):646-54. PubMed ID: 9731553 [TBL] [Abstract][Full Text] [Related]
18. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Tsai MH; Iwakiri Y; Cadelina G; Sessa WC; Groszmann RJ Gastroenterology; 2003 Nov; 125(5):1452-61. PubMed ID: 14598261 [TBL] [Abstract][Full Text] [Related]
19. Influence of nitric oxide synthase and cyclooxygenase blockade on expression of cyclooxygenase and hemodynamics in rats with portal hypertension. Cao H; Xu J; Liu H; Meng FB; Qiu JF; Wu ZY Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):564-9. PubMed ID: 17085343 [TBL] [Abstract][Full Text] [Related]
20. Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Sumanovski LT; Battegay E; Stumm M; van der Kooij M; Sieber CC Hepatology; 1999 Apr; 29(4):1044-9. PubMed ID: 10094944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]